title: [Treatment standards of the oral anticoagulant in patients with idiopathic pulmonary embolism].
abstract: The optimal and the most effective treatment of pulmonary embolism is still a matter of concern and each day sees a new set of challenges for the world of medicine. The progress, has been made in recent years, improved quality of life and caused much better treatment results. This is difficult issue in patients, receiving anticoagulant therapy, because they require an individual approach and adjustability to the therapeutic possibilities. The benefits of long-term anticoagulant therapy, which decreases relapses of idiopathic venous thromboembolism and diminishes risk of thromboembolic complications, should be taking under consideration. It is still a matter of dispute the time of carrying out of treatment, especially after the first life idiopathic episode of pulmonary embolism. The purpose of this paper is an overview and a summary of the foregoing achievements concerned the standards of idiopathic pulmonary embolism treatment, expecting benefits flowing with using new oral anticoagulants, as an alternative to known for decades Vitamin K antagonist drugs. A lot of information about new oral anticoagulants speaks in favor of their use, but unknown safety of the drugs caused searching the best strategy of pulmonary embolism treatment all the time.
authors: I Department of Internal Diseases, Voyevodish Hospital of John Paul II in Bełchatów, Poland.
authors: Zbigniew
authors: Z
authors: Kowalski
authors: I Department of Internal Diseases, Voyevodish Hospital of John Paul II in Bełchatów, Poland.
authors: Piotr
authors: P
authors: Kowalski
authors: I Department of Internal Diseases, Voyevodish Hospital of John Paul II in Bełchatów, Poland.
authors: Damian
authors: D
authors: Grzegorek
mesh_terms: D000284:Administration, Oral; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants
keywords: new oral anticoagulants; pulmonary embolism; vitamin K antagonist